Coverage-gated living condition brief

Overweight peptide evidence brief

A cited Overweight peptide evidence brief across 65 exact-label ClinicalTrials.gov records, 11 connected profiles, and 6 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.

Registry records

65 selected records.

Connected peptides

11 profiles.

Registry update years

2015–2026 in selected records.

Direct collection answer · published August 17, 2026

What peptide evidence does PeptideScanner carry for Overweight?

PeptideScanner’s selected collection contains 65 retained ClinicalTrials.gov records carrying the exact condition label “Overweight,” connected to 11 peptide profiles across 6 registry-update years.

That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Overweight, and it is not a safety or efficacy assessment.

Indication intelligence

Selected evidence landscape

Trial phases4

Phase labels copied from the retained ClinicalTrials.gov versions.

Registry statuses4

Overall statuses at each retained observation, not necessarily current today.

Across the connected peptide profiles, PeptideScanner also carries 243 selected PubMed records and 9 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Overweight unless their own cited source says so.

Related profile context

Literature connected through these peptide profiles

All literature facets →

This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Overweight.

Eloralintide · source record 2026-08-15

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.

PubMed lists PMID 41559929 in Diabetes, obesity & metabolism as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase I, Multicenter Study, with publication-date metadata of 2026-01-20 (day precision). PeptideScanner associated the retained record with the identity slug eloralintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Orforglipron · source record 2026-11-09

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.

PubMed lists PMID 41994902 in Diabetes, obesity & metabolism as Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Maridebart cafraglutide · source record 2026-08-13

Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.

PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Collection change ledger

Recently changed records on this condition hub

All recent changes →

These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.

Record added

ClinicalTrials.gov record NCT00392925

PeptideScanner retained ClinicalTrials.gov record NCT00392925 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was metreleptin.

PeptideScanner change date
November 16, 2026
Cited source date
April 14, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00673387

PeptideScanner retained ClinicalTrials.gov record NCT00673387 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-15, and PeptideScanner's reviewed identity mapping was metreleptin.

PeptideScanner change date
November 16, 2026
Cited source date
April 15, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00710814

PeptideScanner retained ClinicalTrials.gov record NCT00710814 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-11-16, and PeptideScanner's reviewed identity mapping was metreleptin.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2015
Evidence lane
Clinical trials

Exact-record source chronology

Overweight registry timeline

All trial facets →

Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.

2026

58 records

2025

1 record

2024

1 record

2021

1 record

2020

1 record

2015

3 records
What this brief cannot answer